Welcome to LookChem.com Sign In|Join Free
  • or
Home > Products >  > 

Mitomycin C

Related Products

Hot Products

Basic Information post buying leads Suppliers
Name

Mitomycin C

EINECS 200-008-6
CAS No. 50-07-7 Density 1.564 g/cm3
Solubility soluble in water Melting Point 360 °C
Formula C15H18N4O5 Boiling Point 581.78 °C at 760 mmHg
Molecular Weight 334.37 Flash Point 305.65 °C
Transport Information UN 3462 6.1/PG 2 Appearance dark blue grey crystalline powder
Safety 36/37-45-28A-28-53-22 Risk Codes 25-40-22-45-26/27/28
Molecular Structure Molecular Structure of 50-07-7 (Mitomycin C) Hazard Symbols ToxicT,HarmfulXn,VeryT+
Synonyms

Azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione,6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-,(1aS,8S,8aR,8bS)-;Mitomycin C (6CI,7CI);Ametycine;MMC;MitoExtra;Mitomycin;Mitonco;Mitoplus;Mytomycin Kyowa S;NSC26980;Mito-C;A0049 1,4-Dihydroxy-2-tetraprenylbenzene derivative;

 

Mitomycin C Chemical Properties

Product Name: Mitomycin C
Synonyms: (1aS,8S,8aR,8bS)-6-Amino-8a-methoxy-5-methyl-4,7-dioxo-1,1a,2,4,7,8,8a,8b-octahydroazireno[2',3':3,4]pyrrolo[1,2-a]indol-8-yl]methyl carbamate ; [(1aS,8S,8aR,8bS)-6-Amino-8a-methoxy-5-methyl-4,7-dioxo-1,1a,2,4,7,8,8a,8b-octahydroazireno[2',3':3,4]pyrrolo[1,2-a]indol-8-yl]methylcarbamat ; [1aS-(1aa,8b,8aa,8ba)]-6-Amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione ; Azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, 6-amino-1,1a,2,8,8a,8b-hexahydro-8-[(hydroxyiminomethoxy)methyl]-8a-methoxy-5-methyl-, (1aS,8S,8aR,8bS)- ;azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, 6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-, (1aS,8S,8aR,8bS)- ;carbamate de [(1aS,8S,8aR,8bS)-6-amino-8a-méthoxy-5-méthyl-4,7-dioxo-1,1a,2,4,7,8,8a,8b-octahydroaziréno[2',3':3,4]pyrrolo[1,2-a]indol-8-yl]méthyle ;MitoExtra ;Mito-medac ;Mitomycin C derivative ;Mitomycin derivative
Product Categories: Antibiotics;Antibiotic Explorer;Intermediates & Fine Chemicals;Pharmaceuticals;Antibiotics G-MAntibiotics;AntibioticsStem Cell Expansion;AziridinesStem Cell Biology;DissociationAntibiotics;Interferes with DNA SynthesisMore...Close...;Antibiotics A to;Antibiotics by Application;AntibioticsAntibiotics;Antineoplastic and Immunosuppressive AntibioticsAntibiotics;Cell Culture;Chemical Structure Class;Culture;Mechanism of Action;Reagents and Supplements;Stem Cell Isolation;AziridinesAntibiotics;Core Bioreagents;Interferes with DNA Synthesis;Research Essentials
Molecular Structure:
Molecular Formula : C15H18N4O5
Molecular Weight: 334.33
CAS NO: 50-07-7
EINECS : 200-008-6
Merck : 13,6236
Index of Refraction: 1.68
Surface Tension: 77.2 dyne/cm
Density: 1.56 g/cm3
Flash Point: 305.6 °C
Enthalpy of Vaporization: 86.99 kJ/mol
Boiling Point: 581.8 °C at 760 mmHg
Vapour Pressure: 1.59E-13 mmHg at 25°C
Melting point : 360 ºC
Water solubility : soluble
Storage temp. 2-8°C
Solubility H2O: 4 mL/vial Stock solutions should be filter sterilized and stored at 2-8 °C in the dark., clear to slightly hazy, blue to purple
Stability: Stable. Incompatible with strong acids, strong bases, strong oxidizing agents.
Blue-Violet Crystals
 

Mitomycin C Uses

 Mitomycin C (CAS NO.50-07-7) is an antitumor antibiotic.

Mitomycin C Production

 Raw materials :Dichloromethane-->streptomyces avermifilis
 Mitomycin C (CAS NO.50-07-7) is obtained by the separation and purification of inoculum of the soil actinomycete strain .

Mitomycin C Toxicity Data With Reference

 

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
bird - wild LD50 oral 7500ug/kg (7.5mg/kg)   Archives of Environmental Contamination and Toxicology. Vol. 12, Pg. 355, 1983.
 
cat LDLo intravenous 2500ug/kg (2.5mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

BEHAVIORAL: ATAXIA

GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"
Cancer Research. Vol. 20, Pg. 1354, 1960.
 
dog LD50 intravenous 720ug/kg (0.72mg/kg)   Drugs in Japan Vol. -, Pg. 1129, 1990.
man TDLo unreported 1350ug/kg/21W (1.35mg/kg) KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)"

BLOOD: NORMOCYTIC ANEMIA
Archives of Internal Medicine. Vol. 143, Pg. 803, 1983.
 
monkey LDLo intravenous 1mg/kg (1mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

BLOOD: HEMORRHAGE

GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"
Cancer Research. Vol. 20, Pg. 1354, 1960.
 
mouse LD50 intraperitoneal 4mg/kg (4mg/kg)   Journal of Antibiotics, Series A. Vol. 13, Pg. 27, 1960.
mouse LD50 intravenous 4mg/kg (4mg/kg)   Journal of Antibiotics, Series A. Vol. 13, Pg. 27, 1960.
mouse LD50 oral 23mg/kg (23mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"
Cancer Research. Vol. 20, Pg. 1354, 1960.
 
mouse LD50 subcutaneous 7300ug/kg (7.3mg/kg)   Japanese Journal of Cancer Research. Vol. 80, Pg. 670, 1989.
 
mouse LD50 unreported 12mg/kg (12mg/kg)   Cancer Research. Vol. 46, Pg. 2703, 1986.
 
mouse LDLo intratracheal 4mg/kg (4mg/kg)   Toxicology Letters. Vol. 30, Pg. 63, 1986.
 
quail LD50 oral > 100mg/kg (100mg/kg)   Ecotoxicology and Environmental Safety. Vol. 6, Pg. 149, 1982.
rabbit LD50 intravenous 3400ug/kg (3.4mg/kg)   Drugs in Japan Vol. -, Pg. 1129, 1990.
rat LD50 intraperitoneal 2mg/kg (2mg/kg)   Advances in Teratology. Vol. 3, Pg. 181, 1968.
rat LD50 intravenous 3mg/kg (3mg/kg)   Arzneimittel-Forschung. Drug Research. Vol. 20, Pg. 1467, 1970.
 
rat LD50 oral 30mg/kg (30mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"
Cancer Research. Vol. 20, Pg. 1354, 1960.
 
rat LD50 subcutaneous 3250ug/kg (3.25mg/kg)   Drugs in Japan Vol. 6, Pg. 798, 1982.
women TDLo intravenous 1800ug/kg (1.8mg/kg) LUNGS, THORAX, OR RESPIRATION: FIBROSING ALVEOLITIS

LUNGS, THORAX, OR RESPIRATION: DYSPNEA
Lancet. Vol. 2, Pg. 1037, 1980.
women TDLo unreported 2100ug/kg/40W (2.1mg/kg) BLOOD: OTHER HEMOLYSIS WITH OR WITHOUT ANEMIA

BLOOD: OTHER CHANGES
Archives of Internal Medicine. Vol. 143, Pg. 1617, 1983.
 

Mitomycin C Safety Profile

 Hazard Codes T,T+,Xn
Risk Statements 25-40-22-45-26/27/28
R25 :Toxic if swallowed.
R40:Limited evidence of a carcinogenic effect.
R22:Harmful if swallowed.
R45:May cause cancer.
R26/27/28:Very toxic by inhalation, in contact with skin and if swallowed.
Safety Statements 36/37-45-28-53-22
S36/37:Wear suitable protective clothing and gloves.
S45:In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)
S28:After contact with skin, wash immediately with plenty of soap-suds.
S53:Avoid exposure - obtain special instructions before use.
S22:Do not breathe dust.
RIDADR UN 3462 6.1/PG 2
WGK Germany 3
RTECS CN0700000
F 8-10
HazardClass 6.1(a)
PackingGroup II

Mitomycin C Specification

1.General Description :Blue-violet crystals. Used as an anti-tumor antibiotic complex.
2.Air & Water Reactions :Water soluble.
3.Reactivity Profile: Mitomycin C is sensitive to prolonged exposure to light. Mitomycin C may be sensitive to prolonged exposure to air. Mitomycin C is incompatible with strong oxidizing agents, strong acids and strong bases. Calcium salts may cause decomposition.
4.Health Hazard: Toxic doses as low as 750 mg/kg have been reported in humans. The major toxic effect is myelosuppression, characterized by marked leukopenia and thrombocytopenia; this may be delayed and cumulative. Interstitial pneumonia and glomerular damage resulting in kidney failure are unusual but well documented complications. Lung conditions -- administration of mitomycin has been recognized as causing pneumonitis, alveolitis and pulmonary fibrosis. Kidney conditions -- administration of Mitomycin Can cause kidney damage. Kidney toxicity was observed in 1-5 percent of patients. Depressed immune conditions.
5.Fire Hazard :Flash point data for Mitomycin C are not available; however, Mitomycin C is probably combustible.

Please post your buying leads,so that our qualified suppliers will soon contact you!
*Required Fields